Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL trial
2023-507256-76-00Phase 4Authorised
- Sponsor
- GETAID
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab in autoimmune colitis (2 arms), sponsored by GETAID. Primary endpoint: Endoscopic remission at week 48. Planned start Jan 2020; status: authorised.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-507256-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507256-76-00.